Clinical Trial

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce symptoms of depression. Since this medication helps the body make metabolites known as ketone bodies which can serve as an alternate energy source for the brain, the investigators can also test whether ketone bodies help with depressed mood.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-02-24; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2023-03-17
Trial Details
NCT Number NCT05757791
Lead Sponsor NYU Langone Health
Collaborators: American Society of Clinical Psychopharmacology
Conditions Major Depressive Disorder
Enrollment 16 participants
Start Date 2023-03-17
Primary Completion 2026-04 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-03